Calcitonin gene-related peptide in inflammatory bowel disease and experimentally induced colitis.
Pronounced changes in gut neuropeptide content have been observed in colonic tissues from animals with acute experimental colitis and in some patients with inflammatory bowel disease. The early decrease of CGRP in the colon during colitis in the animal studies suggest that CGRP is released during the inflammatory process. No data are available showing the biological action of released CGRP during inflammation. The sensory neurotoxin capsaicin was used in animal studies to examine the effect of sensory nerves on inflammation and healing in experimental animal models. The severity of colitis was enhanced after capsaicin pretreatment in acute and chronic animal models of colitis. These data support the hypothesis that sensory nerves exert a protective and healing-promoting function in the gut. CGRP is a good candidate for this action of sensory nerves because it is a major component in sensory nerve fibers. How CGRP exerts its protective function in the intestine is unknown. Data from gastric ulcer models support the hypothesis that a main action of CGRP is regulation of mesenteric and mucosal blood flow resulting in enhanced protection and tissue healing. Other effector roles of CGRP afferent nerve endings could also be considered.
Eysselein
V E
VE
Inflammatory Bowel Disease Center, Harbor-UCLA Medical Center, Torrance 90509.
Reinshagen
M
M
Patel
A
A
Davis
W
W
Nast
C
C
Sternini
C
C
D000818:Animals; D015740:Calcitonin Gene-Related Peptide / Q000502:physiology*; D002211:Capsaicin / Q000494:pharmacology; D003093:Colitis, Ulcerative / Q000503:physiopathology*; D003106:Colon / Q000294:innervation; D003714:Denervation; D004195:Disease Models, Animal; D007249:Inflammation; D015212:Inflammatory Bowel Diseases / Q000503:physiopathology*; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D009475:Neurons, Afferent / Q000502:physiology
D015740:Calcitonin Gene-Related Peptide; D002211:Capsaicin